Disease status and disease burden at the moment of the study visit of axial and peripheral phenotypes with regard to the presence of psoriasis. Univariate analysis
| . | . | Axial phenotypea . | Peripheral phenotypeb . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | Overall population (n = 2296) . | Psoriatic axial phenotype (a) (n = 287) . | Non-psoriatic axial phenotype (b) (n = 1688) . | P-value . | Psoriatic peripheral phenotype (c) (n = 256) . | Non-psoriatic peripheral phenotype (d) (n = 65) . | P-value . | P-value psoriatic axial phenotype vs psoriatic peripheral phenotype (a vs c) . | P-value non-psoriatic axial phenotype vs non-psoriatic peripheral phenotype (b vs d) . |
| Number of swollen joints (current), mean (s.d.) | 0.5 (1.8) | 1.0 (2.7) | 0.4 (1.7) | <0.001 | 1.8 (3.7) | 0.9 (1.8) | 0.056 | 0.010 | 0.046 |
| MASES enthesis index (current), mean (s.d.) | 1.7 (1.9) | 2.3 (2.1) | 1.6 (1.9) | 0.005 | 0.7 (1.3) | 0.8 (0.8) | 0.871 | <0.001 | <0.001 |
| Heel enthesitis (current), n/n (%) | 144/2296 (6.3) | 24/287 (8.4) | 103/1688 (6.1) | 0.149 | 7/256 (2.7) | 10/65 (15.4) | <0.001 | 0.005 | 0.007 |
| Pain or limitation of the hip on physical examination, n/n (%) | 406/2265 (17.9) | 48/280 (17.1) | 340/1667 (20.4) | 0.207 | 15/253 (5.9) | 3/65 (4.6) | 0.683 | <0.001 | 0.002 |
| Oral corticosteroids (current), n/n (%) | 256/2264 (11.3) | 37/279 (13.3) | 145/1666 (8.7) | 0.016 | 59/254 (23.2) | 15/65 (23.1) | 0.979 | 0.003 | <0.001 |
| csDMARDs (current), n/n (%) | 661/2269 (29.1) | 130/281 (46.3) | 353/1672 (21.1) | <0.001 | 148/252 (58.7) | 30/64 (46.9) | 0.088 | 0.004 | <0.001 |
| Anti-TNF treatment (current), n/n (%) | 364/2263 (16.1) | 61/278 (21.9) | 265/1667 (15.9) | 0.012 | 30/254 (11.8) | 8/64 (12.5) | 0.879 | 0.002 | 0.464 |
| CRP, mean (s.d.), mg/l | 8.6 (13.4) | 9.0 (15.0) | 8.7 (13.7) | 0.770 | 7.9 (10.2) | 5.8 (7.4) | 0.138 | 0.332 | 0.005 |
| ESR, mean (s.d.), mm/h | 18.0 (15.9) | 17.6 (16.4) | 18.0 (16.1) | 0.718 | 19.8 (15.2) | 14.0 (10.7) | 0.004 | 0.123 | 0.005 |
| ASDAS-CRP, mean (s.d.) | 2.5 (1.1) | 2.6 (1.1) | 2.5 (1.1) | 0.254 | 2.4 (1.1) | 1.9 (1.2) | 0.001 | 0.044 | <0.001 |
| VAS nocturnal pain last week, mean (s.d.), 0–10 | 3.6 (3.0) | 3.6 (2.9) | 3.8 (2.9) | 0.174 | 2.3 (2.9) | 1.9 (2.6) | 0.224 | <0.001 | <0.001 |
| VAS pain last week, mean (s.d.), 0–10 | 3.8 (2.8) | 3.8 (2.8) | 4.0 (2.7) | 0.197 | 2.5 (2.9) | 2.2 (2.7) | 0.430 | <0.001 | <0.001 |
| Patient global assessment last week, mean (s.d.), 0–10 | 4.4 (2.7) | 4.6 (2.6) | 4.5 (2.7) | 0.406 | 4.2 (2.8) | 3.3 (2.9) | 0.014 | 0.104 | <0.001 |
| Physician global assessment last week, mean (s.d.), 0–10 | 3.0 (2.1) | 3.4 (2.2) | 3.1 (2.1) | 0.053 | 2.5 (2.1) | 2.3 (2.2) | 0.450 | <0.001 | 0.002 |
| BASDAI, mean (s.d.), 0–10 | 4.0 (2.4) | 4.3 (2.4) | 4.0 (2.4) | 0.038 | 4.0 (2.5) | 2.9 (2.5) | 0.004 | 0.087 | <0.001 |
| BASFI, mean (s.d.), 0–10 | 3.5 (2.7) | 3.8 (2.6) | 3.6 (2.7) | 0.373 | 2.8 (2.6) | 1.9 (2.3) | 0.013 | <0.001 | <0.001 |
| SF-12 mental component, mean (s.d.), 0–100 | 47.8 (12.4) | 47.3 (13.5) | 47.9 (12.5) | 0.455 | 48.3 (1.9) | 47.5 (10.1) | 0.042 | 0.338 | 0.802 |
| SF-12 physical component, mean (s.d.), 0–100 | 35.7 (11.1) | 34.9 (11.7) | 35.6 (11.1) | 0.328 | 36.8 (10.5) | 39.7 (10.0) | 0.589 | 0.046 | 0.003 |
| . | . | Axial phenotypea . | Peripheral phenotypeb . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | Overall population (n = 2296) . | Psoriatic axial phenotype (a) (n = 287) . | Non-psoriatic axial phenotype (b) (n = 1688) . | P-value . | Psoriatic peripheral phenotype (c) (n = 256) . | Non-psoriatic peripheral phenotype (d) (n = 65) . | P-value . | P-value psoriatic axial phenotype vs psoriatic peripheral phenotype (a vs c) . | P-value non-psoriatic axial phenotype vs non-psoriatic peripheral phenotype (b vs d) . |
| Number of swollen joints (current), mean (s.d.) | 0.5 (1.8) | 1.0 (2.7) | 0.4 (1.7) | <0.001 | 1.8 (3.7) | 0.9 (1.8) | 0.056 | 0.010 | 0.046 |
| MASES enthesis index (current), mean (s.d.) | 1.7 (1.9) | 2.3 (2.1) | 1.6 (1.9) | 0.005 | 0.7 (1.3) | 0.8 (0.8) | 0.871 | <0.001 | <0.001 |
| Heel enthesitis (current), n/n (%) | 144/2296 (6.3) | 24/287 (8.4) | 103/1688 (6.1) | 0.149 | 7/256 (2.7) | 10/65 (15.4) | <0.001 | 0.005 | 0.007 |
| Pain or limitation of the hip on physical examination, n/n (%) | 406/2265 (17.9) | 48/280 (17.1) | 340/1667 (20.4) | 0.207 | 15/253 (5.9) | 3/65 (4.6) | 0.683 | <0.001 | 0.002 |
| Oral corticosteroids (current), n/n (%) | 256/2264 (11.3) | 37/279 (13.3) | 145/1666 (8.7) | 0.016 | 59/254 (23.2) | 15/65 (23.1) | 0.979 | 0.003 | <0.001 |
| csDMARDs (current), n/n (%) | 661/2269 (29.1) | 130/281 (46.3) | 353/1672 (21.1) | <0.001 | 148/252 (58.7) | 30/64 (46.9) | 0.088 | 0.004 | <0.001 |
| Anti-TNF treatment (current), n/n (%) | 364/2263 (16.1) | 61/278 (21.9) | 265/1667 (15.9) | 0.012 | 30/254 (11.8) | 8/64 (12.5) | 0.879 | 0.002 | 0.464 |
| CRP, mean (s.d.), mg/l | 8.6 (13.4) | 9.0 (15.0) | 8.7 (13.7) | 0.770 | 7.9 (10.2) | 5.8 (7.4) | 0.138 | 0.332 | 0.005 |
| ESR, mean (s.d.), mm/h | 18.0 (15.9) | 17.6 (16.4) | 18.0 (16.1) | 0.718 | 19.8 (15.2) | 14.0 (10.7) | 0.004 | 0.123 | 0.005 |
| ASDAS-CRP, mean (s.d.) | 2.5 (1.1) | 2.6 (1.1) | 2.5 (1.1) | 0.254 | 2.4 (1.1) | 1.9 (1.2) | 0.001 | 0.044 | <0.001 |
| VAS nocturnal pain last week, mean (s.d.), 0–10 | 3.6 (3.0) | 3.6 (2.9) | 3.8 (2.9) | 0.174 | 2.3 (2.9) | 1.9 (2.6) | 0.224 | <0.001 | <0.001 |
| VAS pain last week, mean (s.d.), 0–10 | 3.8 (2.8) | 3.8 (2.8) | 4.0 (2.7) | 0.197 | 2.5 (2.9) | 2.2 (2.7) | 0.430 | <0.001 | <0.001 |
| Patient global assessment last week, mean (s.d.), 0–10 | 4.4 (2.7) | 4.6 (2.6) | 4.5 (2.7) | 0.406 | 4.2 (2.8) | 3.3 (2.9) | 0.014 | 0.104 | <0.001 |
| Physician global assessment last week, mean (s.d.), 0–10 | 3.0 (2.1) | 3.4 (2.2) | 3.1 (2.1) | 0.053 | 2.5 (2.1) | 2.3 (2.2) | 0.450 | <0.001 | 0.002 |
| BASDAI, mean (s.d.), 0–10 | 4.0 (2.4) | 4.3 (2.4) | 4.0 (2.4) | 0.038 | 4.0 (2.5) | 2.9 (2.5) | 0.004 | 0.087 | <0.001 |
| BASFI, mean (s.d.), 0–10 | 3.5 (2.7) | 3.8 (2.6) | 3.6 (2.7) | 0.373 | 2.8 (2.6) | 1.9 (2.3) | 0.013 | <0.001 | <0.001 |
| SF-12 mental component, mean (s.d.), 0–100 | 47.8 (12.4) | 47.3 (13.5) | 47.9 (12.5) | 0.455 | 48.3 (1.9) | 47.5 (10.1) | 0.042 | 0.338 | 0.802 |
| SF-12 physical component, mean (s.d.), 0–100 | 35.7 (11.1) | 34.9 (11.7) | 35.6 (11.1) | 0.328 | 36.8 (10.5) | 39.7 (10.0) | 0.589 | 0.046 | 0.003 |
Values shown in bold are considered significant: P-value <0.05. aAxial phenotype: defined as the presence of definite radiographic sacroiliitis according to the local reader OR presence of IBP according to the Calin criteria. bPeripheral phenotype: defined as absence of definite radiographic sacroiliitis according to the local reader AND absence of IBP AND presence of peripheral involvement (either arthritis, or enthesitis or dactylitis). Values shown in bold are considered significant. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score; csDMARD: conventional synthetic DMARD; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SF-12: short form of the Medical Outcomes Study Short Form-36; VAS: visual analogue scale.
Disease status and disease burden at the moment of the study visit of axial and peripheral phenotypes with regard to the presence of psoriasis. Univariate analysis
| . | . | Axial phenotypea . | Peripheral phenotypeb . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | Overall population (n = 2296) . | Psoriatic axial phenotype (a) (n = 287) . | Non-psoriatic axial phenotype (b) (n = 1688) . | P-value . | Psoriatic peripheral phenotype (c) (n = 256) . | Non-psoriatic peripheral phenotype (d) (n = 65) . | P-value . | P-value psoriatic axial phenotype vs psoriatic peripheral phenotype (a vs c) . | P-value non-psoriatic axial phenotype vs non-psoriatic peripheral phenotype (b vs d) . |
| Number of swollen joints (current), mean (s.d.) | 0.5 (1.8) | 1.0 (2.7) | 0.4 (1.7) | <0.001 | 1.8 (3.7) | 0.9 (1.8) | 0.056 | 0.010 | 0.046 |
| MASES enthesis index (current), mean (s.d.) | 1.7 (1.9) | 2.3 (2.1) | 1.6 (1.9) | 0.005 | 0.7 (1.3) | 0.8 (0.8) | 0.871 | <0.001 | <0.001 |
| Heel enthesitis (current), n/n (%) | 144/2296 (6.3) | 24/287 (8.4) | 103/1688 (6.1) | 0.149 | 7/256 (2.7) | 10/65 (15.4) | <0.001 | 0.005 | 0.007 |
| Pain or limitation of the hip on physical examination, n/n (%) | 406/2265 (17.9) | 48/280 (17.1) | 340/1667 (20.4) | 0.207 | 15/253 (5.9) | 3/65 (4.6) | 0.683 | <0.001 | 0.002 |
| Oral corticosteroids (current), n/n (%) | 256/2264 (11.3) | 37/279 (13.3) | 145/1666 (8.7) | 0.016 | 59/254 (23.2) | 15/65 (23.1) | 0.979 | 0.003 | <0.001 |
| csDMARDs (current), n/n (%) | 661/2269 (29.1) | 130/281 (46.3) | 353/1672 (21.1) | <0.001 | 148/252 (58.7) | 30/64 (46.9) | 0.088 | 0.004 | <0.001 |
| Anti-TNF treatment (current), n/n (%) | 364/2263 (16.1) | 61/278 (21.9) | 265/1667 (15.9) | 0.012 | 30/254 (11.8) | 8/64 (12.5) | 0.879 | 0.002 | 0.464 |
| CRP, mean (s.d.), mg/l | 8.6 (13.4) | 9.0 (15.0) | 8.7 (13.7) | 0.770 | 7.9 (10.2) | 5.8 (7.4) | 0.138 | 0.332 | 0.005 |
| ESR, mean (s.d.), mm/h | 18.0 (15.9) | 17.6 (16.4) | 18.0 (16.1) | 0.718 | 19.8 (15.2) | 14.0 (10.7) | 0.004 | 0.123 | 0.005 |
| ASDAS-CRP, mean (s.d.) | 2.5 (1.1) | 2.6 (1.1) | 2.5 (1.1) | 0.254 | 2.4 (1.1) | 1.9 (1.2) | 0.001 | 0.044 | <0.001 |
| VAS nocturnal pain last week, mean (s.d.), 0–10 | 3.6 (3.0) | 3.6 (2.9) | 3.8 (2.9) | 0.174 | 2.3 (2.9) | 1.9 (2.6) | 0.224 | <0.001 | <0.001 |
| VAS pain last week, mean (s.d.), 0–10 | 3.8 (2.8) | 3.8 (2.8) | 4.0 (2.7) | 0.197 | 2.5 (2.9) | 2.2 (2.7) | 0.430 | <0.001 | <0.001 |
| Patient global assessment last week, mean (s.d.), 0–10 | 4.4 (2.7) | 4.6 (2.6) | 4.5 (2.7) | 0.406 | 4.2 (2.8) | 3.3 (2.9) | 0.014 | 0.104 | <0.001 |
| Physician global assessment last week, mean (s.d.), 0–10 | 3.0 (2.1) | 3.4 (2.2) | 3.1 (2.1) | 0.053 | 2.5 (2.1) | 2.3 (2.2) | 0.450 | <0.001 | 0.002 |
| BASDAI, mean (s.d.), 0–10 | 4.0 (2.4) | 4.3 (2.4) | 4.0 (2.4) | 0.038 | 4.0 (2.5) | 2.9 (2.5) | 0.004 | 0.087 | <0.001 |
| BASFI, mean (s.d.), 0–10 | 3.5 (2.7) | 3.8 (2.6) | 3.6 (2.7) | 0.373 | 2.8 (2.6) | 1.9 (2.3) | 0.013 | <0.001 | <0.001 |
| SF-12 mental component, mean (s.d.), 0–100 | 47.8 (12.4) | 47.3 (13.5) | 47.9 (12.5) | 0.455 | 48.3 (1.9) | 47.5 (10.1) | 0.042 | 0.338 | 0.802 |
| SF-12 physical component, mean (s.d.), 0–100 | 35.7 (11.1) | 34.9 (11.7) | 35.6 (11.1) | 0.328 | 36.8 (10.5) | 39.7 (10.0) | 0.589 | 0.046 | 0.003 |
| . | . | Axial phenotypea . | Peripheral phenotypeb . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| . | Overall population (n = 2296) . | Psoriatic axial phenotype (a) (n = 287) . | Non-psoriatic axial phenotype (b) (n = 1688) . | P-value . | Psoriatic peripheral phenotype (c) (n = 256) . | Non-psoriatic peripheral phenotype (d) (n = 65) . | P-value . | P-value psoriatic axial phenotype vs psoriatic peripheral phenotype (a vs c) . | P-value non-psoriatic axial phenotype vs non-psoriatic peripheral phenotype (b vs d) . |
| Number of swollen joints (current), mean (s.d.) | 0.5 (1.8) | 1.0 (2.7) | 0.4 (1.7) | <0.001 | 1.8 (3.7) | 0.9 (1.8) | 0.056 | 0.010 | 0.046 |
| MASES enthesis index (current), mean (s.d.) | 1.7 (1.9) | 2.3 (2.1) | 1.6 (1.9) | 0.005 | 0.7 (1.3) | 0.8 (0.8) | 0.871 | <0.001 | <0.001 |
| Heel enthesitis (current), n/n (%) | 144/2296 (6.3) | 24/287 (8.4) | 103/1688 (6.1) | 0.149 | 7/256 (2.7) | 10/65 (15.4) | <0.001 | 0.005 | 0.007 |
| Pain or limitation of the hip on physical examination, n/n (%) | 406/2265 (17.9) | 48/280 (17.1) | 340/1667 (20.4) | 0.207 | 15/253 (5.9) | 3/65 (4.6) | 0.683 | <0.001 | 0.002 |
| Oral corticosteroids (current), n/n (%) | 256/2264 (11.3) | 37/279 (13.3) | 145/1666 (8.7) | 0.016 | 59/254 (23.2) | 15/65 (23.1) | 0.979 | 0.003 | <0.001 |
| csDMARDs (current), n/n (%) | 661/2269 (29.1) | 130/281 (46.3) | 353/1672 (21.1) | <0.001 | 148/252 (58.7) | 30/64 (46.9) | 0.088 | 0.004 | <0.001 |
| Anti-TNF treatment (current), n/n (%) | 364/2263 (16.1) | 61/278 (21.9) | 265/1667 (15.9) | 0.012 | 30/254 (11.8) | 8/64 (12.5) | 0.879 | 0.002 | 0.464 |
| CRP, mean (s.d.), mg/l | 8.6 (13.4) | 9.0 (15.0) | 8.7 (13.7) | 0.770 | 7.9 (10.2) | 5.8 (7.4) | 0.138 | 0.332 | 0.005 |
| ESR, mean (s.d.), mm/h | 18.0 (15.9) | 17.6 (16.4) | 18.0 (16.1) | 0.718 | 19.8 (15.2) | 14.0 (10.7) | 0.004 | 0.123 | 0.005 |
| ASDAS-CRP, mean (s.d.) | 2.5 (1.1) | 2.6 (1.1) | 2.5 (1.1) | 0.254 | 2.4 (1.1) | 1.9 (1.2) | 0.001 | 0.044 | <0.001 |
| VAS nocturnal pain last week, mean (s.d.), 0–10 | 3.6 (3.0) | 3.6 (2.9) | 3.8 (2.9) | 0.174 | 2.3 (2.9) | 1.9 (2.6) | 0.224 | <0.001 | <0.001 |
| VAS pain last week, mean (s.d.), 0–10 | 3.8 (2.8) | 3.8 (2.8) | 4.0 (2.7) | 0.197 | 2.5 (2.9) | 2.2 (2.7) | 0.430 | <0.001 | <0.001 |
| Patient global assessment last week, mean (s.d.), 0–10 | 4.4 (2.7) | 4.6 (2.6) | 4.5 (2.7) | 0.406 | 4.2 (2.8) | 3.3 (2.9) | 0.014 | 0.104 | <0.001 |
| Physician global assessment last week, mean (s.d.), 0–10 | 3.0 (2.1) | 3.4 (2.2) | 3.1 (2.1) | 0.053 | 2.5 (2.1) | 2.3 (2.2) | 0.450 | <0.001 | 0.002 |
| BASDAI, mean (s.d.), 0–10 | 4.0 (2.4) | 4.3 (2.4) | 4.0 (2.4) | 0.038 | 4.0 (2.5) | 2.9 (2.5) | 0.004 | 0.087 | <0.001 |
| BASFI, mean (s.d.), 0–10 | 3.5 (2.7) | 3.8 (2.6) | 3.6 (2.7) | 0.373 | 2.8 (2.6) | 1.9 (2.3) | 0.013 | <0.001 | <0.001 |
| SF-12 mental component, mean (s.d.), 0–100 | 47.8 (12.4) | 47.3 (13.5) | 47.9 (12.5) | 0.455 | 48.3 (1.9) | 47.5 (10.1) | 0.042 | 0.338 | 0.802 |
| SF-12 physical component, mean (s.d.), 0–100 | 35.7 (11.1) | 34.9 (11.7) | 35.6 (11.1) | 0.328 | 36.8 (10.5) | 39.7 (10.0) | 0.589 | 0.046 | 0.003 |
Values shown in bold are considered significant: P-value <0.05. aAxial phenotype: defined as the presence of definite radiographic sacroiliitis according to the local reader OR presence of IBP according to the Calin criteria. bPeripheral phenotype: defined as absence of definite radiographic sacroiliitis according to the local reader AND absence of IBP AND presence of peripheral involvement (either arthritis, or enthesitis or dactylitis). Values shown in bold are considered significant. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score; csDMARD: conventional synthetic DMARD; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SF-12: short form of the Medical Outcomes Study Short Form-36; VAS: visual analogue scale.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
